Fiona Li, MD
Psychiatry · Oklahoma City, OKNPI 1336175009
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 24.1% of the total. 2025 is the largest year on record at $1,448, 2.6 times the $563 reported in 2019.
Across 180 payments — averaging $29.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$965
- Johnson & Johnson$616
- Supernus Pharmaceuticals, Inc.$467
- Alkermes, Inc.$394
- Neurocrine Biosciences, Inc.$358
- plus $1K from 16 others
What the payments were for
- Food & beverage$5,292100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $1,279 |
| Otsuka America Pharmaceutical, Inc. | 24 | $965 |
| Johnson & Johnson | 18 | $616 |
| Supernus Pharmaceuticals, Inc. | 10 | $467 |
| Alkermes, Inc. | 12 | $394 |
| Neurocrine Biosciences, Inc. | 18 | $358 |
| Teva Pharmaceuticals USA, Inc. | 10 | $278 |
| Axsome Therapeutics, Inc. | 6 | $121 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $117 |
| Lundbeck LLC | 5 | $112 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $98 |
| Sunovion Pharmaceuticals Inc. | 1 | $80 |
| E.r. Squibb & Sons, L.L.C. | 4 | $74 |
| Merck | 4 | $62 |
| Corium, LLC | 2 | $61 |
| Indivior Inc. | 3 | $59 |
| Harmony Biosciences LLC | 3 | $55 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $22 |
| Bioxcel Therapeutics, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Almatica Pharma LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$584
- LYBALVI$480
- VRAYLAR$335
- QELBREE$237
- INVEGA SUSTENNA$203
- INVEGA TRINZA$203
- SPRAVATO$141
- UZEDY$116
How this compares
$5,299 in reported general payments places this provider in the 85th percentile of 328 psychiatry providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 17 | $139,719 |
| RexultiBrexpiprazole | 41 | $74,066 |
| VraylarCariprazine Hcl | 39 | $62,961 |
| Abilify MaintenaAripiprazole | 21 | $58,283 |
| TrintellixVortioxetine Hydrobromide | 40 | $30,569 |
| LybalviOlanzapine/Samidorphan Malate | 18 | $28,429 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 185 | $9,979 |
| Bupropion XlBupropion Hcl | 301 | $8,291 |
| Hydroxyzine Hcl | 339 | $7,711 |
| Duloxetine Hcl | 392 | $7,077 |
| Quetiapine Fumarate | 386 | $7,057 |
| Vilazodone Hcl | 48 | $6,450 |
| Trazodone Hcl | 581 | $5,360 |
| Olanzapine | 245 | $5,258 |
| Mirtazapine | 176 | $4,301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $358 | $139,71917 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $965 | $132,34962 claims |
| AbbVieVraylar | $1,279 | $62,96139 claims |
| Alkermes, Inc.Lybalvi | $394 | $28,42918 claims |
| Lilly USA, LLCOlanzapine | $22 | $5,258245 claims |
| Almatica Pharma LLCSertraline Hcl | $18 | $985102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Oklahoma City
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
- Marvin PeytonOklahoma City$60K
- Josephine DeguzmanOklahoma City$38K
- Haisam Al KhouriOklahoma City$10K
- Patrick HornOklahoma City$8K
- Shreekuma VinekarOklahoma City$7K
- Relindis TitaOklahoma City$6K
- Janita ArdisOklahoma City$6K
- Ahsan KhanOklahoma City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.